AAMC Home   Tomorrow's Doctors Tomorrow's Cures
  Home  Government Affairs   Newsroom   Meetings   Publications Shopping Cart   Site Map    

Washington Highlights: March 17, 2006

Senate Approves Specter-Harkin Amendment to Increase Health, Education Funding

The Senate March 16 approved, by a vote of 51 to 49, the FY 2007 budget resolution (S. Con. Res. 83). By a vote of 73 to 27, the Senate passed an amendment offered by Senators Arlen Specter (R-Pa.) and Tom Harkin (D-Iowa), the chair and ranking member of the Senate Labor-HHS-Education Appropriations Subcommittee, respectively, to provide an additional $7 billion in discretionary spending over the budget resolution approved March 9 by the Senate Budget Committee [see Washington Highlights, March 10]. The Specter-Harkin amendment would provide an additional $7 billion in funding for priority health and education programs, including NIH, CDC, HRSA, vocational education, K-12 and higher education.

The Senate also approved an amendment by Sen. Richard Burr (R-N.C.) to create a reserve fund for pandemic influenza preparedness planning after rejecting an amendment by Sen. Kent Conrad (D-N.D.) that would have increased funding for pandemic flu preparedness by $5 billion. The Senate also defeated an amendment by Sen. Edward Kennedy (D-Mass.) that would have added $6.3 billion to the discretionary spending cap to increase education funding. The Senate also defeated a Conrad amendment to require offsets for tax cuts and new mandatory spending programs.

The budget resolution establishes an $873 billion spending cap for discretionary programs in FY 2007 and includes a controversial reconciliation instruction to open the Arctic National Wildlife Refuge to energy exploration. Confronted with increasing resistance from Senators concerned about election year impacts, Senate leaders abandoned plans to seek further reductions in Medicare and other mandatory spending or to increase tax cuts further.

The House will not take up its version of the budget resolution until after next week's recess.

Information:
Dave Moore, Senior Director
AAMC Government Relations
dbmoore@aamc.org
(202) 828-0525

Hospital Groups Urge Passage of Children's GME Legislation

The AAMC joined fellow associations in a March 13 letter to leaders of the House Energy and Commerce Committee, urging swift mark-up and passage of legislation to reauthorize the federal Children's Hospitals Graduate Medical Education (CHGME) payment program. The American Hospital Association and National Association of Children's Hospitals also signed onto the letter.

Referring to bipartisan support for the "Children's Hospitals Education Equity and Research Act" (H.R. 1246), the letter also urged rejection of "the administration's proposal to cut funding for the program by two-thirds and limit the remaining funds only to financially weak hospitals." The letter states, "the [administration's] proposal ignores the CHGME program's purpose of providing comparable federal GME support to independent children's hospitals, its success in strengthening children's hospitals ability to contribute to the future workforce of physicians who care for children, and the impact of the virtual elimination of the program on hospitals that face numerous challenges."

The Senate passed its version (S. 285) of the CHGME reauthorization last July.

Information:
Lynne Davis Boyle, Assistant Vice President
AAMC Government Relations
ldavisboyle@aamc.org
(202) 828-0526

AAMC Criticizes OMB Proposed Risk Assessment Standards

The AAMC urged the Office of Management and Budget (OMB) in a March 10 comment letter to restrict the reach of proposed new standards for risk assessments in federal agencies. The OMB announced Jan. 17 its "proposed bulletin" for risk assessments in the Federal Register, continuing the Administration's avowed efforts to improve the quality and reliability of statistical and other information used or released by the federal government. The latest proposed bulletin would, in addition to setting standards, provide for additional levels of review and certification for risk assessments that influence major decisions in the private or public sectors.

"Our chief concern," the AAMC noted in its comments, "is that announcements or other actions important to public health not be subject to protracted delay, managerial impediments, or, frankly, 'second-guessing' by other individuals or agencies." The Association offered the example of a decision by a data safety and monitoring board to interdict a clinical trial based on clear evidence of asymmetric benefit or risk; such determinations, once made, must be acted on decisively.

The AAMC argued that the final risk assessment bulletin should include a provision parallel to the recent OMB Information Quality Guidelines on Peer Review, wherein "time-sensitive health and safety disseminations" are specifically excluded from the requirements laid out in that bulletin. In general, the AAMC believes that a final bulletin should defer to the judgment of the U.S. Public Health Service's leadership "on the timeliness or urgency of making decisions based on the adequacy of a risk assessment, in consideration with all other factors."

Public comments on the OMB bulletin are due June 15. OMB has also asked the National Academies to review the proposed risk assessment standards.

Information:
Stephen Heinig, Lead Science Policy Analyst
AAMC Biomedical Health Sciences Research
sheinig@aamc.org
(202) 828-0488

Thomas Blasts OIG for Failure to Regulate Provider Pricing

In a March 10 letter to Department of Human Health and Services (HHS) Secretary Michael Leavitt, House Ways and Means Committee Chairman Bill Thomas (R-Calif.) urged that a 2003 proposed rule by the HHS Office of Inspector General (OIG) to define "excessive charges" be finalized to ensure "the integrity of the Medicare Trust Fund and the success of the President's recent initiative to increase health care price transparency."

The letter states, "It is unacceptable that the OIG refuses to move forward on this rule. The OIG apparently choose to sacrifice the interests of taxpayers over those who wish to keep real prices shrouded in order to gouge the public, employers and insurers."

The OIG has the authority to exclude from Medicare an individual or entity that has submitted a bill "for items or services furnished substantially in excess of the individual's or entity's usual charges." The OIG proposed to define the terms "substantially in excess" and "usual charges" 3 times-- in 1990 and 1997, and most recently in 2003. In 1997, the OIG noted that the increasing use of fee schedules could limit the application of the law which applies when a claim is made on a charge or cost basis.

However, in the preamble to the 2003 proposed rule, the OIG wrote, "the fee schedule is not an entitlement, but a cap on the amount that Medicare will pay for the item or service." The OIG also noted that in many cases Medicare payments may be "substantially more than the payments that providers have agreed to accept from most or all of their other third party payers." This situation prompted the OIG to propose the 2003 rule that, once again, was strongly opposed by the provider community.

In its comment letter, the AAMC strongly opposed the 2003 proposed rule for the following reasons: (1) the OIG does not have the authority to promulgate such a rule; (2) the rule does not reflect Congressional intent; (3) the rule is unworkable, burdensome, and would cause institutions to incur huge expenses; and (4) one consequence of the proposed methodology would be the elimination of sliding scale fees that often are used by hospitals that treat large numbers of indigent patients.

Information:
Lynne Davis Boyle, Assistant Vice President
AAMC Government Relations
ldavisboyle@aamc.org
(202) 828-0526

Ivy Baer, Director & Regulatory Counsel
AAMC Health Care Affairs
ibaer@aamc.org
(202) 828-0490

MedPAC Focuses on "Efficient" Provider

At its March 9-10 meeting, the Medicare Payment Advisory Commission (MedPAC) focused on two factors, efficiency and cost-effectiveness, as important determinants in a provider pay-for-performance mechanism.

MedPAC continued its work to identify efficient providers, as defined by a combination of quality and resource use. For physicians, MedPAC discussed methods to attribute "episodes of care," (groups of claims data related to a specific condition) to individual physicians. The pilot project which used a national sample of beneficiaries will be re-run using full data for six markets, so that the Commission can evaluate the issues of implementing a reporting system. For hospitals, MedPAC staff unveiled their analysis of potential methodologies for using quality indicators to study quality of care, but did not focus on resource use at this time.

MedPAC also discussed potential methods to revise the practice expense (PE) component of the physician fee schedule to more accurately reflect costs. PE accounts for approximately 42 percent of Medicare payments to physicians. Options presented include updating practice cost database through surveys and re-assessing underlying assumptions for incorporating the cost of equipment.

MedPAC staff also presented a summary of their research on coordinating care for chronically ill patients and suggested two models to implement care coordination in Medicare fee-for-service. Both models would pay for care coordination, using an at-risk fee, and a separate fee to either the provider or the provider organization. For integrated entities, the integrated entity would provide the coordination. For smaller entities, an external care management firm would provide the coordination of care. MedPAC also observed that current patient evaluation and management codes might need to be revised to account for time spent with complex patients.

Continuing its work from last spring, MedPAC's expert panel presented an analysis designed to assess the opportunities and challenges of using cost effectiveness in Medicare. The panel noted that in spite of the variation found in the methods used, there are numerous studies in the cost-effectiveness literature that can provide estimates of the costs and clinical benefits of services - particularly those that are high profile and high cost. A discussion of the challenges of obtaining cost-effectiveness information and using it for reimbursement purposes followed the presentation. Members agreed that cost-effectiveness information should not necessarily be used to deny coverage of services, but rather pay differentially depending on the cost-benefit analysis. Because much of the challenge lies in setting service payment levels, Commissioners are looking at various ways in which to tackle it by, among other things, taking a look at other countries' experiences in this arena.

Another issue that surfaced during the discussion was the challenge of obtaining cost-effectiveness information when the literature does not provide a clear indication of the effectiveness of care. To that end, three questions would need to be resolved: who would sponsor the research, who would conduct it and who would fund it. Particularly with regard to the last question, the issue of a public/private partnership was debated.

MedPAC's next public meeting is April 19-20.

Information:
Mary Patton, Senior Specialist
AAMC Health Care Affairs
mpatton@aamc.org
(202) 862-6297

Diana Mayes, Specialist
AAMC Health Care Affairs
dmayes@aamc.org
(202) 828-0498

House Approves Higher Ed Extension

The House March 14 approved a fourth extension of the Higher Education Act, as the current extension is scheduled to expire March 31 [see Washington Highlights, Dec. 23, 2005]. House Education and Workforce Chair Howard "Buck" McKeon (R-Calif.) sponsored the "Higher Education Extension Act of 2006" (H.R. 4911), which will extend the reauthorization deadline to June 30. The Senate is expected to pass the bill.

Information:
Matthew Shick, Senior Legislative Analyst
AAMC Government Relations
mshick@aamc.org
(202) 862-6116

President Nominates von Eschenbach to Head FDA

President Bush March 15 nominated Andrew von Eschenbach, M.D., to be Commissioner of the Food and Drug Administration (FDA). He has served as acting head of the agency since September 2005, while also serving as Director of the National Cancer Institute.